Understanding of Psychotic Disorders in Children With 22q11.2DS
Launched by HÔPITAL LE VINATIER · Nov 17, 2020
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "PremiCeS22" is focused on understanding early signs of psychotic disorders in children who have a condition called 22q11.2 Deletion Syndrome. This syndrome can affect how children develop and may lead to mental health challenges as they grow. The researchers aim to identify warning signals that could indicate the beginning of these disorders, helping to provide better support and treatment options for affected children.
To participate in this study, children must be between 4 and 13 years old and either have a diagnosis of 22q11.2 Deletion Syndrome or no developmental issues at all. They should also be able to speak French. Unfortunately, children with certain intellectual disabilities or those taking specific medications that might affect brain function cannot participate. If eligible, participants will be part of a supportive research environment where their experiences and health will be closely monitored, contributing to a better understanding of how to help children facing these challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of 22q11.2 deletion syndrome or no developmental disease
- • Aged from 4 to 13 years old
- • French language
- Exclusion Criteria:
- • Diagnosis of intellectual deficiency according to DSM 5 criteria
- • Drug prescribed for somatic condition that could influence cerebral functioning
About Hôpital Le Vinatier
Hôpital Le Vinatier is a leading psychiatric hospital located in France, renowned for its commitment to advancing mental health care through innovative research and clinical trials. With a focus on integrating clinical practice and scientific inquiry, the institution aims to enhance treatment protocols and therapeutic outcomes for individuals with psychiatric disorders. Hôpital Le Vinatier collaborates with multidisciplinary teams of healthcare professionals and researchers to conduct rigorous studies, ensuring the highest standards of ethical practice and patient safety. Its dedication to improving mental health services makes it a pivotal player in the field of psychiatric research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lyon, Rhone Alpes, France
Patients applied
Trial Officials
Marie-Noëlle BABINET
Principal Investigator
CH LE VINATIER
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials